| abstract |
Disclosed is a pharmaceutical composition for treating, ameliorating or preventing disorders associated with changes in iron levels, which can increase iron bioavailability. A pharmaceutical composition comprising a lipocalin mutein having a binding affinity for hepcidin or a fragment thereof. Disorders associated with changes in iron levels include anemia, anemia due to inflammation, chronic inflammatory anemia, iron deficiency anemia, iron load anemia, sepsis, hereditary hemochromatosis, anemia associated with chronic kidney disease (CKD), Anemia associated with cancer (AC), chemotherapy-induced anemia (CIA), or anemia associated with ESA resistance. [Selection figure] None |